Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Study of Thymus Transplantation in DiGeorge Anomaly
NCT00576836Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Sep 2004
- Primary completion
- Nov 2010
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rethymic in DiGeorge syndrome (DGS) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Survival at 1 Year Post-CTTI. Started Sep 2004; status: completed.
02
Drugs
Rethymic
03
Conditions
DiGeorge syndrome (DGS)
Beyond the preview
Go deeper on NCT00576836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576836.